Vinpocetine for acute ischaemic stroke.
BACKGROUND
Vasoactive and neuroprotective drugs are used to treat stroke in some countries.


OBJECTIVE
The objective of this review was to assess the effect of vinpocetine in acute ischaemic stroke.


METHODS
We searched the Cochrane Stroke Group trials register (last searched: August 1999) and Medline. We contacted researchers in the field and drug companies.


METHODS
Unconfounded randomised trials of vinpocetine compared with placebo, or any other reference treatment, in people with acute stroke. Trials were included if treatment started no later than 14 days after stroke onset.


METHODS
Two reviewers independently applied the inclusion criteria. One reviewer extracted the data that was then checked by the second reviewer. Trial quality was assessed.


RESULTS
One trial involving 40 patients was included. Data for 33 patients were reported. No deaths occurred in the trial and no significant difference in dependency was shown between the treatment and placebo groups. No adverse effects were reported.


CONCLUSIONS
There is not enough evidence to evaluate the effect of vinpocetine on survival or dependency of patients with acute stroke.
Bereczki
D
D
Department of Neurology, University Medical School of Debrecen, Nagyerdei krt. 98, Debrecen, Hungary, H-4012. bereczki@jaguar.dote. hu
Fekete
I
I
D002545:Brain Ischemia / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D018696:Neuroprotective Agents; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C013983:vinpocetine